Standards SPPPT
Standards SPPPT
Definitions 2
Standards 5
Standard 1: Act professionally 10
Standard 16: Ensure proper procedures and environment when administering a drug, blood product or vaccine 47
Standard 17: Ensure patient safety when administering a drug, blood product or vaccine 48
Standard 22: Limits on insertion or removal of instruments, devices, or fingers under section 45(1)(d)(i)
and (ii) of the Health Professions Restricted Activity Regulation 60
Standard 23: Prohibition of, and reporting requirements for, female genital mutilation 61
AppendixA 62
These standards are part of and must be read in the overall legislative scheme that regulates the practice of pharmacists,
the practice of pharmacy technicians, the operation of pharmacies, and the sale of food and drug products, which
includes
Pharmacists and pharmacy technicians practising in Alberta must know, understand and comply with this overall
legislative scheme.
These standards are mandatory. They set out the minimum acceptable standard of practice for pharmacists and
pharmacy technicians.
For each standard, there is a basic statement of principle followed by detailed rules set out in the application of standard.
Both the basic statement of principle and the detailed rules are mandatory.
c) additional prescribing authorization means authorization to prescribe under Sections 16(3) and
(4) of the Pharmacists and Pharmacy Technicians Profession Regulation;
i. facilitate communication,
ii. determine mutual goals of therapy that are acceptable to the patient,
iv. establish the expectations of each regulated health professional when working with a
mutual patient;
e) emergency means a circumstance where a patient urgently requires a professional service that
includes a restricted activity for the purposes of preventing imminent mortality or morbidity.
f) employee means an individual employed in a pharmacy who is not a regulated member and
includes a volunteer who works in a pharmacy;
ii. natural health products as defined in the Natural Health Products Regulations (Canada);
and
iii. products, aids and devices that promote health and treat diseases, dysfunctions and
disorders;
i) herd means a group or population of animals that cohabitate and feed together in the same
environment and includes flocks, schools, or hives;
j) medically important antimicrobial means an antimicrobial drug or class of drugs used in human
medicine that can also be used in animals1;
1 A comprehensive list of medically important antimicrobials appears on List A, the document entitled List of Certain Antimicrobial Active
Pharmaceutical Ingredients, that is published by the Government of Canada on its website, as amended from time to time.
i. in the case of a human who is the patient, a family member, caregiver or another
individual who has a close personal relationship with the patient; and
ii. in the case of an animal who is the patient, an owner, an agent or employee of an owner,
or caregiver of the animal or herd;
n) pharmacist service means any service that falls within the practice of pharmacists;
p) pharmacy technician service means any service that falls within the practice of pharmacy
technicians;
q) practice of pharmacists means the scope of practice described in Section 3(1) of Schedule 19 to
the Health Professions Act;
r) practice of pharmacy technicians means the scope of practice described in Section 3(2) of
Schedule 19 to the Health Professions Act;
s) prescriber means
t) prescribing at initial access means prescribing a drug or blood product under Sections 16(3) and
(4) of the Pharmacists and Pharmacy Technicians Profession Regulation when the patient does
not have a current prescription or has not recently had a prescription;
u) prescribing to manage ongoing therapy means prescribing a drug or blood product under
Sections 16(3) and (4) of the Pharmacists and Pharmacy Technicians Profession Regulation
when the patient has a current prescription or has recently had a prescription;
v) professional service means any service that falls within the practice of pharmacists or the
practice of pharmacy technicians;
i. in respect of a patient who is a human, a relationship formed with a patient for the
purpose of optimizing the patient’s health or drug therapy; and
i. in the case of humans, a health professional who practises under the terms of the Health
Professions Act or similar legislation that governs a health profession in Alberta; and
ii. in the case of animals, a veterinarian or veterinary technologist who practises under the
terms of the Veterinary Profession Act.
aa) restricted activity3 means an activity named as a restricted activity in Section 2 of Schedule 7.1
of the Government Organization Act;
ab) withdrawal time has the same meaning as in the Animal Health Act.
2. Unless these standards provide a more specific definition, terms used in these standards have the same meaning
as in Schedule 19 to the Health Professions Act, the Pharmacists and Pharmacy Technicians Profession
Regulation, the Pharmacy and Drug Act, or the Pharmacy and Drug Regulation4.
3. All provisions in these standards that are applicable to Schedule 1 drugs also apply to blood products, with all
necessary modifications.
4. Where a provisional pharmacist, courtesy pharmacist or student pharmacist engages in the practice of
pharmacists, that provisional pharmacist, courtesy pharmacist or student pharmacist must comply with those
standards applicable to the practice of a clinical pharmacist.
5. Where a provisional or courtesy pharmacy technician engages in the practice of pharmacy technicians, that
provisional or courtesy pharmacy technician must comply with those standards applicable to a pharmacy
technician.
6. Where a patient is an animal, all duties under these standards that contemplate communication from a patient or
that require communication with a patient must be read as requiring communication from or with the patient’s
agent.
7. Where a patient is an animal, all duties under these standards that contemplate when an animal may enter the
food chain should be read to include an animal or any animal products that may enter the food chain for human
consumption.
2 “residue” means medicine, chemicals, or deleterious substances or their metabolized products remaining in animals, animal products, animal
by-products, or animal tissues;
3 The concept of “restricted activities” only applies to human beings.
4 For example:
Section 1 of the Pharmacy and Drug Act, which defines compound (b.1), council (c), dispense (d) and drug (e); and
Section 1 of the Pharmacy and Drug Regulation, which defines dispensary (1)(e), patient services area (1)(h), prescription department (2)(a).
Pharmacists and pharmacy technicians must establish and maintain professional relationships with their
patients.
Pharmacists must determine whether a patient has or is likely to have a drug therapy problem.
If a pharmacist determines that a patient has or is likely to have a drug therapy problem, the pharmacist must take
appropriate action.
If a pharmacy technician determines that a patient has or is likely to have drug therapy problem, the pharmacy
technician must refer the patient to a pharmacist so that the pharmacist can take appropriate action.
Each time a pharmacist or a pharmacy technician dispenses a Schedule 1 drug or blood product pursuant to a
prescription:
b) the pharmacist or the pharmacy technician must determine that the prescription is current, authentic, and
complete.
Each time a pharmacist or a pharmacy technician dispenses a Schedule 1 drug or blood product pursuant to a
prescription, the pharmacist or the pharmacy technician must ensure that:
Releaseofdrugsandprovidingpatientswithsufficientinformation
• Standard 8:
Each time a pharmacist or a pharmacy technician dispenses a Schedule 1 drug or blood product pursuant to a
prescription, or sells a Schedule 2 drug:
a) the pharmacist or the pharmacy technician must confirm the patient’s identity, and
b) the pharmacist must provide the patient with sufficient information to enable the patient to receive the
intended benefit of the drug therapy.
A pharmacist or a pharmacy technician must take reasonable steps to offer assistance to a patient who wishes to
purchase a Schedule 3 drug or a health care product, aid or device.
Each time a pharmacist or a pharmacy technician compounds a drug or a blood product, the pharmacist or the
pharmacy technician must ensure that the compounded drug or blood product is prepared according to:
A pharmacist who prescribes a Schedule 1 drug or blood product must understand the regulatory framework in
relation to pharmacist prescribing and must comply with it.
A pharmacist who adapts an existing prescription under Sections 16(1)(e) and (f) of the Pharmacists and
Pharmacy Technicians Profession Regulation must:
A pharmacist who prescribes for emergency purposes under Sections 16(1)(g) and (h) of the Pharmacists and
Pharmacy Technicians Profession Regulation must:
a) be satisfied that it is not reasonably possible for the patient to see another health professional to obtain
the prescription,
c) only prescribe the minimum amount of the drug or blood product necessary to give the patient sufficient
time to see a prescriber.
b) a recommendation from a prescriber that the patient receive a Schedule 1 drug or blood product, or
A pharmacist who prescribes a drug or blood product at initial access based on the pharmacist’s own assessment
of the patient must not dispense the drug him or herself, unless:
a) the pharmacist is satisfied that adhering to this standard will compromise the health of the patient, or
Ensure proper procedures and environment when administering a drug, blood product
or vaccine
• Standard 16:
b) ensure that the environment in which the drug, blood product or vaccine is to be administered is
appropriate.
A pharmacist who administers a drug, blood product or vaccine must have proper regard for the interests of the
patient and take all steps necessary to ensure that the drug, blood product or vaccine is administered safely.
A pharmacist must create and maintain patient records for the pharmacist services provided by that pharmacist.
A pharmacy technician must create and maintain patient records for pharmacy technician services provided by
that technician.
Neither a pharmacist nor a pharmacy technician may accept the return of a drug or a health care product, aid or
device for reuse.
A pharmacist who provides direction to a pharmacy technician must do so in accordance with this standard.
A pharmacist who supervises others in the practice of pharmacists or the practice of pharmacy technicians, or a
pharmacy technician who supervises others in the practice of pharmacy technicians must:
a) ensure that the person being supervised acts within the limits established by the legislative scheme, and
b) remain responsible for the delivery of all components of any restricted activity that requires the
professional skills and training of the pharmacist or the pharmacy technician.
A pharmacist or a pharmacy technician who repackages drugs must take appropriate steps to protect patient
safety.
In the practice of a pharmacist, a pharmacist must not insert or remove instruments, devices or fingers beyond
the anal verge or beyond the labia majora, except if
b) it is an emergency;
c) the patient is not able to take the drug or medication orally or the drug or medication requires intra-anal or
intra-vaginal administration to achieve the intended therapeutic effect; and
d) another appropriately authorized regulated health professional is not readily available to insert or remove
instruments, devices or fingers beyond the anal verge or beyond the labia major for the purpose of the
administration of the drug or medication.
A pharmacist or pharmacy technician must not procure, perform or have any role in the procurement or
performance of female genital mutilation and is responsible for reporting any such conduct in accordance with
the requirements of the Health Professions Act.
Application of Standard 1
1.1 Pharmacists and pharmacy technicians must practice in accordance with the law that governs each of
their practices, including but not limited to:
a) the Health Professions Act, its regulations, these standards;
b) the Pharmacy and Drug Act, its regulations, and the Standards for the Operation of Licensed
Pharmacies;
f) the Controlled Drugs and Substances Act, and its regulations, including the Narcotic Control
Regulations;
1.2 In approaching the law that governs their practices, pharmacists and pharmacy technicians must comply
with its letter and its spirit to ensure that the public and each patient receive the full protection of the law.
1.3 Pharmacists and pharmacy technicians have a duty to be aware of changes in the law that governs their
practices and adjust their practices to ensure compliance with the changes.
1.4 When required to serve the best interests of the patient, each pharmacist and pharmacy technician must
work collaboratively with colleagues, including other regulated health professionals, in the provision of
pharmacist and pharmacy technician services. This obligation includes but is not limited to:
a) treating colleagues with respect,
d) making appropriate and efficient use of the expertise and availability of colleagues, and
1.5 A pharmacist must not provide pharmacist services to a patient who cannot be appropriately treated
within the practice of pharmacists.
1.6 A pharmacy technician must not provide pharmacy technician services to a patient who cannot be
appropriately treated within the practice of pharmacy technicians.
1.7 A pharmacist must:
a) only practice within the practice of pharmacists;
that the pharmacist is authorized and competent to perform and that are applicable to the
pharmacist’s practice and the procedure being performed.
i. the activities of compounding, dispensing and selling drugs for animals; and
ii. the prescribing of drugs for the purpose of renewing a prescription to dispense a
Schedule 1 drug, schedule 2 drug, or blood product to ensure continuity of care
that the pharmacist is competent to perform and that are applicable to the pharmacist’s practice;
d) be aware of the limits of the pharmacist’s personal competence and only provide pharmacist
services within these limitations; and
e) be aware of the circumstances in which the pharmacist should refer the patient to another
appropriately qualified regulated health professional, including when:
i. the pharmacist does not have the training, experience or skills necessary to address the
patient’s needs;
ii. the condition of the patient cannot be effectively treated within the practice of
pharmacists; or
iii. the patient’s condition has not adequately or appropriately responded to drug therapy or
other therapy within the practice of pharmacists.
b) only engage in restricted activities that the pharmacy technician is authorized and competent to
perform, and that are applicable to the pharmacy technician’s practice and the procedure being
performed;
c) For animals, only engage the activities of compounding, dispensing and selling drugs that the
pharmacy technician is competent to perform and that are applicable to the pharmacy
technician’s practice;
d) be aware of the limits of the pharmacy technician’s personal competence and only provide
services within these limitations; and
e) be aware of circumstances in which the pharmacy technician should refer the patient to a
pharmacist, including when:
ii. alerts are generated by the pharmacy software system during entry or processing of a
prescription that require therapeutic knowledge, clinical analysis or assessment; or
iii. the patient asks questions or seeks information that requires therapeutic knowledge,
clinical analysis or assessment.
1.10 Each pharmacist and pharmacy technician must participate in the quality assurance processes required
by the Standards for the Operation of Licensed Pharmacies or another workplace quality assurance
program applicable to the pharmacists’ or the pharmacy technicians’ practice.
1.11 A pharmacist who provides patient care in an environment where a quality assurance program does not
exist or does not meet the minimum standards established under the Standards for the Operation of
Licensed Pharmacies must implement a program that meets or exceeds the requirements outlined in the
Standards for the Operation of Licensed Pharmacies.
Appearance,demeanourandidentificationasaregulatedpharmacyprofessional
1.12 When engaged in their practices, each pharmacist and pharmacy technician must:
a) maintain a professional appearance and demeanour; and
b) be readily identifiable to the public, other regulated health professionals and other workers in the
health care system as a pharmacist or pharmacy technician as the case may be.
1.13 A pharmacist must not practice under conditions that compromise the pharmacist’s professional
independence, judgment or integrity.
1.14 A pharmacy technician must not practice under conditions that compromise the pharmacy technician’s
professional independence, judgment or integrity.
1.15 No pharmacist or pharmacy technician may impose conditions on another pharmacist, pharmacy
technician or other regulated health professional that compromises the other professional’s
independence, judgment or integrity.
1.16 Neither a pharmacist nor a pharmacy technician may:
a) accept gifts or other benefits from, or
a patient, regulated health professional or any other person that could have the effect of compromising
his or her professional independence, judgment or integrity.
1.17 Nothing in Standard 1.14 to 1.16 limits the obligation of a pharmacy technician to practice under the
direction of a clinical pharmacist or courtesy pharmacist in accordance with Schedule 19, Section 3(2) of
the Health Professions Act and Section 21 of the Pharmacists and Pharmacy Technicians Profession
Regulation.
1.18 In Standard 1.19 and 1.20:
a) “inducement” means
i. a reward,
iii. a prize,
iv. a coupon,
v. points or other mechanisms in incentive or loyalty programs that can be redeemed for
rewards, gifts, cash, prizes or other goods or services; and
i. a Schedule 1 drug,
1.19 A regulated member must not offer or provide or be party to the offering or provision of an inducement to
a patient where the inducement is offered or provided on the condition that the patient obtains:
a) a drug product, or
b) a professional service
i. is required for compassionate reasons based on the circumstances of the patient, and
b) the provision of a drug product, professional service or health care product, aid or device to
augment drug therapy or augment a professional service provided by a regulated member.
1.21 Nothing in Standard 1.19 is intended to limit a regulated member from taking any steps required or
necessary to comply with the law that governs the practice of pharmacy referred to in Standard 1.1.
1.22 A pharmacist must not prescribe a drug or blood product for:
a) the pharmacist,
c) anyone else with whom the pharmacist has a close personal relationship;
except for minor conditions, in an emergency, or when another prescriber is not readily available to
prescribe the drug or blood product.
RequirementtobetrainedinCPRandfirstaid
1.23 A pharmacist must maintain current certificates in cardiopulmonary resuscitation (CPR) and first aid, at a
level determined by Council, if the pharmacist has been authorized to administer drugs by injection.
Facilitating compliance with the Protection of Students with Life Threatening Allergies Act
1.24 Subject to the directions of Council, a pharmacist or a pharmacy technician practising with the
pharmacist may sell epinephrine auto-injectors to an individual authorized by a school board5 to purchase
epinephrine auto-injectors to be maintained in a school under the Protection of Students with Life
Threatening Allergies Act despite the requirements in these standards respecting identification,
assessment, communication, documentation and record keeping on a patient specific basis.
5 As defined within the Protection of Students with Life-Threatening Allergies Act (2019).
1.25 A regulated member must not use the title “specialist” in connection with the provision of a pharmacy
service unless authorized to do so by Council.
Application of Standard 2
2.1 A pharmacist must:
a) establish a professional relationship with each patient to whom the pharmacist provides services,
d) take all information collected into consideration when providing the pharmacist services, and
b) assist the pharmacist in identifying the patient’s health needs and expectations,
c) collect the information required to provide pharmacy related services to the patient,
ii. determining whether the patient must be referred to the pharmacist; and
2.3 In the case of a patient who is a human, each pharmacist and pharmacy technician must deal directly
with the patient unless:
a) it is in the best interest of the patient for the pharmacist or the pharmacy technician to deal with
the patient’s agent,
b) the pharmacist is satisfied that a regulated health professional acting within the scope of their
profession is responsible for the administration of drugs to the patient.
2.4 In the case of a patient who is a human, the following factors may be taken into account in determining
whether dealing with a patient’s agent is in the best interests of the patient:
a) the express wishes of the patient,
e) the patient’s absence from the area where the service is being provided.
2.5 All standards applicable to the relationship between the pharmacist or pharmacy technician and the
patient apply to the pharmacist or pharmacy technician and the patient’s agent with the necessary
modifications to make them effective.
2.7 A pharmacist and a pharmacy technician must honour a patient’s request to transfer care to another
health professional.
2.8 As soon as reasonably possible after receipt of a request from a patient to transfer care to another
pharmacist, the pharmacist or the pharmacy technician must provide to the pharmacist of the patient’s
choice:
a) transfer of active prescriptions with remaining refills that can be legally transferred; and
b) other information that, in the opinion of the transferring pharmacist, may be required to ensure
continuity of care, including but not limited to:
b) have reasonable grounds for ceasing to provide care to the patient and document those reasons
on the patient record, and
c) give advance notice of the intention to terminate care and provide a timeline that is
commensurate with the continuing care needs of the patient.
2.10 Notwithstanding Standard 2.9, a pharmacist may terminate a relationship with a patient without providing
advance notice if:
a) the patient poses a risk to the pharmacist, pharmacy staff or other patients;
c) the pharmacist is leaving the practice location and another pharmacist will assume the practice
in the same location; or
d) the pharmacist is leaving practice because of personal illness or other urgent circumstances; and
the pharmacist provides for continuity of care by offering to provide information to another pharmacist.
Application of Standard 3
3.1 A pharmacist must consider appropriate information to assess the patient and the patient’s health history
and history of drug therapy each time:
a) the pharmacist:
iii. provides advice to a patient about a drug, a blood product or drug therapy.
3.2 Notwithstanding Standard 3.1(b), a pharmacist may delay the assessment of a patient if the pharmacist
is satisfied that:
a) drugs are dispensed in frequent, limited quantities only to assist patient to self-administer or to
comply with distribution processes in institutions; or
3.3 A pharmacist who delays an assessment under Standard 3.2 must ensure that appropriate information to
assess the patient and the patient’s health history and history of drug therapy is completed each time a
new prescription or drug order is received, or every 90 days, whichever comes first.
c) treatment history for the condition including drug therapy and outcomes;
d) age;
f) allergies or intolerances to drugs, excipients or other products that may affect drug therapy;
h) other health care products, aids and devices or other products being used that may affect the
pharmacist’s decision;
j) any other information that a reasonable pharmacist would require to provide the pharmacist
service.
c) identity of other regulated health professionals or caregivers who are providing care to the
patient;
d) diagnosis;
e) laboratory values;
g) lifestyle information and social history, including tobacco, alcohol or recreational drug use; and
Application of Standard 4
4.1 A pharmacist must consider whether a patient has a drug therapy problem or is likely to have a drug
therapy problem, each time:
a) the pharmacist:
iii. provides advice to a patient about a drug, a blood product or drug therapy;
4.2 A drug therapy problem includes the following circumstances in relation to a patient:
Application of Standard 5
5.1 If a patient has or is likely to have a drug therapy problem, the pharmacist must determine the appropriate
response.
5.2 A pharmacy technician who determines that a patient has or is likely to have a drug therapy problem must
bring the problem or the potential problem, and any contributing factors identified, to the attention of the
pharmacist for consideration as outlined in Standard 5.1.
5.3 The appropriate response to a drug therapy problem may include any one or more of the following:
a) gathering additional information from the patient, the patient’s health record, the patient’s agent
or another regulated health professional;
b) implementing a plan to monitor the occurrence and impact of the drug therapy problem with
mechanisms for intervention when required;
c) resolving or reducing the drug therapy problem to a clinically acceptable level by adapting a
prescription under Section 16(1)(e) of the Pharmacists and Pharmacy Technicians Profession
Regulation;
d) advising the patient or the prescriber or both about the drug therapy problem and suggesting an
alternative;
e) entering into a collaborative relationship with another regulated health professional to manage
the patient’s drug therapy;
g) in the case of a patient who is a human, reporting an adverse reaction to the original prescriber
and to the Canadian Adverse Drug Reaction Monitoring Program; or
h) in the case of a patient who is an animal, reporting an adverse reaction to the prescribing
veterinarian, and reporting an adverse reaction:
Application of Standard 6
6.1 A pharmacist must determine the appropriateness of a prescription by considering relevant factors that a
reasonable pharmacist would consider in the circumstances.
6.2 For the purposes of Standard 6.1,
a) for all prescriptions for all patients the relevant factors include, but are not limited to whether
ii. the prescription orders a drug or blood product for an indication that is:
vii. the regimen for administration is practical, based on the patient’s functional ability; and
viii. any information was brought to the pharmacist’s attention by a pharmacy technician
involved in the care of the patient;
b) for a refill prescription, in addition to the factors under subsection a), the relevant factors include,
but are not limited to:
c) for a patient that is a human, in addition to the factors under subsection a) and b), where
applicable, the relevant factors include but are not limited to whether:
i. the patient’s organ function, such as renal and hepatic function, will tolerate the drug or
blood product;
d) for a patient that is an animal, in addition to the factors under subsection a) and b), where
applicable, the relevant factors include, but are not limited to, whether:
ii. if the prescription is for a drug containing a medically important antimicrobial; and
iii. there are any other barriers to care that are brought to the pharmacist’s attention by the
patient’s agent;
e) for a patient that is an animal that may enter the food chain, in addition to the factors under
subsection a), b), where applicable, and d), consideration of relevant factors include but are not
limited to when the animal will enter the food chain for human consumption; and
f) for patients in a herd of animals, in addition to the factors under subsection a), b), where
applicable, d) and e), consideration of relevant factors includes, but is not limited to how many
animals in the herd will be treated.
6.3 Before dispensing a prescription, a pharmacist or a pharmacy technician must review the prescription to
determine when it was written.
6.4 Neither a pharmacist nor a pharmacy technician may dispense a drug or blood product under a
prescription that was issued more than one year before the date the drug or blood product is to be
dispensed.
6.5 Neither a pharmacist nor a pharmacy technician may refill a prescription for:
a) a benzodiazepine or other targeted substance, as defined in the regulations to the Controlled
Drugs and Substances Act, for a period of greater than 12 months after the prescription was first
written; or
b) a Schedule 1 drug for a period greater than 18 months after the prescription was first filled.
6.6 Before dispensing a prescription, a pharmacist or a pharmacy technician must determine the authenticity
of the prescription by taking reasonable steps to:
a) identify the prescriber;
b) determine whether the prescriber is legally authorized to prescribe the drug or blood product for
which the prescription has been given; and
6.7 Prior to dispensing a prescription, a pharmacist or a pharmacy technician must determine the
completeness of a prescription by ensuring that the prescription includes the:
a) name and address of the patient, or in the case of a herd of animals, a unique identifier or the
location of the herd;
d) dosage, if applicable;
l) the withdrawal time if the prescription is for an animal that may enter the food chain; and
6.8 In addition to the information required in Standard 6.7, when considering the completeness of a
prescription for medicated feed for animals, a pharmacist or a pharmacy technician must ensure that the
prescription includes:
a) the species, production type and age or weight of the animals to be treated with the medicated
feed;
d) the proper name, or the common name if there is no proper name, of the drug or each of the
drugs, as the case may be, to be used as medicating ingredients in the preparation of the
medicated feed, and the dosage levels of those medicating ingredients;
i. feeding instructions,
ii. a warning statement respecting the withdrawal period to be observed following the use
of the medicated feed, and
iii. where applicable, cautions with respect to animal health or to the handling or storage of
the medicated feed.
6.9 If a pharmacist or a pharmacy technician receives a verbal order for a drug or blood product from a
prescriber, the pharmacist or the pharmacy technician must reduce the prescription to writing and sign or
initial the prescription.
Standards of Practice for Pharmacists and Pharmacy Technicians 24
Follow proper procedures when dispensing
Standard 7: Each time a pharmacist or a pharmacy technician dispenses a Schedule
1 drug or blood product pursuant to a prescription, the pharmacist or the pharmacy
technician must ensure that:
a) theprescriptionisfilledcorrectly,
b) appropriate dispensing procedures are used,
c) the drug or blood product is packaged properly,
d) the container is labeled properly, and
e) afinalcheckisperformed.
Application of Standard 7
7.1 A pharmacist or a pharmacy technician who dispenses a drug or blood product must ensure that:
a) the drug or blood product is correct and in accordance with the prescription; and
b) the dosage form, strength, manufacturer and quantity dispensed are correct and in accordance
with the prescription.
7.2 A pharmacist or a pharmacy technician who dispenses a drug or blood product must ensure that his or
her dispensing procedure:
a) is hygienic,
e) complies with any requirements applicable to the specific drug or blood product.
Proper packaging
7.3 A pharmacist or a pharmacy technician who dispenses a drug or blood product must ensure that the drug
or blood product is dispensed:
a) in an appropriate package, having regard for the nature of the drug or blood product, including
sensitivity to light and temperature; and
ii. the pharmacist or the pharmacy technician is satisfied that child-resistant packaging is
not appropriate,
iii. child-resistant packaging is not suitable because of the form of the drug or blood
product, or
7.4 If a drug or blood product is not dispensed in a child-resistant package, the pharmacist or the pharmacy
technician who dispenses the drug must be satisfied that:
a) the patient has been warned of the risks of not using a child-resistant package, or
Proper labeling
7.5 A pharmacist or a pharmacy technician who dispenses a drug or blood product must ensure that the
container in which the drug or blood product is dispensed has a label that is clearly legible and includes
the following:
a) the name of the patient for whom the drug or blood product is dispensed;
i. generic name, strength and the identity of the manufacturer for single entity drugs;
ii. generic name, strength and the identity of the manufacturer for combination drugs, where
possible, or the brand name and strength;
iv. in the case of a blood product, the name of the blood product;
j) the withdrawal time, if the prescription is for an animal that may enter the food chain.
7.6 The name of the pharmacy under Standard 7.5(b) must be the name provided on the application for
pharmacy licence or another name approved by the Registrar.
7.7 Despite Standard 7.5(d), a pharmacist may use, or direct a pharmacy technician to use, only a Drug
Identification Number (DIN) to identify the drug or blood product on the label in circumstances where:
a) it is in the best interests of the patient or required for the purpose of a medical or scientific
investigation, and
7.8 When it is not practical to affix the prescription label to the drug package, a pharmacist or a pharmacy
technician who dispenses the prescription must ensure that:
a) the prescription label is affixed to the outer container; and
b) another label is attached to the drug package containing, at a minimum, the patient’s name, the
name of the drug and the drug strength.
Procedureifitisnotpracticaltoaffixprescriptiondirectionsonthedrugpackage
7.9 When it is not possible to place complete directions for use on the prescription label, the pharmacist or
the pharmacy technician who dispenses the prescription must ensure that complete written directions are
provided on an instruction sheet accompanying the drug.
Labelingforascientificormedicalinvestigation
7.10 Despite Standard 7.5, if a drug is dispensed as a part of an official scientific or medical investigation, the
drug container may be labeled in a manner appropriate to the investigation as long as the information on
the label ensures that the contents can be readily identified in an emergency.
7.11 Subject to meeting the requirements of Standard 7.5, a pharmacist or a pharmacy technician may use a
form of label that provides additional information or forms of information to facilitate understanding by
patients with special needs, including visually impaired or non-English speaking patients.
7.12 In addition to the labeling requirements described in sections 7.5 to 7.11, when a pharmacist or pharmacy
technician dispenses a drug or blood product for an animal or herd, the label must:
a) state “for veterinary use only”,
b) include a means to identify the specific animal or herd for which the drug is dispensed;
d) include minimal withdrawal time, in the case of an animal or herd that may enter the food chain;
and
i. feeding instructions;
ii. a warning statement respecting the withdrawal period to be observed following the use
of the medicated feed; and
iii. where applicable, cautions with respect to animal health or to the handling or storage of
the medicated feed.
6 Labelling requirements for prescriptions for medicated feed are established by section C.08.012(1)(d)(vi) of the Food and Drug Regulations.
7.13 Standards 7.5 to 7.11 inclusive do not apply if a drug is dispensed to a patient in a health care facility.
Completingthefinalcheck
7.14 A pharmacist or a pharmacy technician who dispenses a drug must perform a final check in order to be
satisfied that each step in the dispensing process has been completed properly by verifying that:
a) the drug dosage form, strength, manufacturer and quantity dispensed are correct according to
the prescription;
b) the prescription label is accurate according to the prescription and contains the information
required under this standard and under federal and provincial legislation; and
7.15 Whenever possible, a final check must be performed by a pharmacist or a pharmacy technician who did
not enter the prescription into the dispensing software system or select the drug from stock.
7.16 A pharmacist or a pharmacy technician who engages in dispensing must ensure that their dispensing
activities are recorded in a clear audit trail that identifies:
a) all individuals who were involved in the processing of a prescription and dispensing of the drug,
and
7.17 If more than one regulated member of the college is involved in dispensing a drug, they must work
together to ensure that:
a) the role and responsibility of each regulated member is clear,
c) the audit trail clearly identifies the regulated member that fulfilled each role and responsibility.
Application of Standard 8
Confirmationofpatient’sidentitywhenadrugorbloodproductisdispensedorsold
8.1 Before the release of a drug or blood product provided under a prescription or the sale of a Schedule 2
drug, the pharmacist or the pharmacy technician who releases the drug or blood product must ensure
communication occurs with the patient to confirm:
a) the identity of the patient, or in the case of animals who live in a herd, the herd;
b) the identity of the drug or blood product being dispensed or sold; and
8.2 In addition to the requirements outlined in Standard 8.1, a pharmacy technician who releases a drug or
blood product provided under a prescription or sells a Schedule 2 drug must:
a) ensure that a pharmacist has:
i. assessed the patient, the patient’s health history and medication record and has
determined that the drug therapy is appropriate for the patient;
ii. evaluated the prescription when the drug is dispensed under a prescription; and
b) if the patient is a human being, inform the patient that a pharmacist is available to speak with
them if desired and refer the patient to the pharmacist for a dialogue if:
ii. the patient asks questions that require therapeutic knowledge, clinical analysis or
assessment;
A. provide the patient with sufficient information to enable the patient to receive the
intended benefit of the drug therapy; or
b) when a Schedule 2 drug is sold to the patient for the first time;
i. provide the patient with sufficient information to enable the patient to receive the
intended benefit of the drug therapy; or
8.4 Despite Standards 8.1 to 8.3, a communication or dialogue with a patient may not be required if the drug
being dispensed or sold will only be administered by or under the supervision of a regulated health
professional acting within the scope of their profession.
Dialoguetobespecifictothepatient
Requiredelementsofthedialoguewhenadrugorbloodproductisdispensedorsoldtoapatientforthefirsttime
c) common or important adverse effects that may apply to the patient and recommendations to
minimize the risk associated with them;
d) signs and symptoms that indicate a therapeutic response, a therapeutic failure or an adverse
reaction;
ii. pose a risk to the patient in conjunction with the drug or blood product; and
8.7 In the case of a dialogue under Standards 8.3(c) or (d), the dialogue must include those components of
Standard 8.6 that, in the professional opinion of the pharmacist, are applicable to the patient.
8.8 A pharmacist may provide written information to a patient to enhance understanding about the patient’s
drug therapy, but the written materials cannot be used to replace the dialogue required under Standards
8.1 and 8.3.
Writtenmaterialsmustbespecifictothepatient
8.9 Subject to Standard 8.8, written materials provided to a patient must specifically address the patient and
the patient’s needs.
8.10 A pharmacist may provide written materials that are general in nature if the pharmacist identifies those
portions of the information that are relevant to the patient.
8.11 If a patient has special needs, including a hearing impairment or inability to speak English, the pharmacist
may use appropriate written materials to assist in counseling the patient.
Application of Standard 9
9.1 A pharmacist must be available and accessible to a person who wishes to purchase a Schedule 3 drug or
a health care product, aid or device.
9.2 A pharmacist must take reasonable steps to enter into a dialogue with or provide information to a person
who:
a) requests a Schedule 3 drug or a health care product, aid or device;
b) requests assistance in making a choice about a Schedule 3 drug or a health care product, aid or
device;
c) appears to be having difficulty in making a choice about a Schedule 3 drug or a health care
product, aid or device;
d) is observed to be making purchases of a Schedule 3 drug or a health care product, aid or device
in a quantity or at a frequency that is therapeutically inappropriate;
e) the pharmacist recognizes as someone who may face a risk from the selection or use of a
Schedule 3 drug or a health care product, aid or device;
f) the pharmacist recognizes as someone purchasing Schedule 3 products for use in an animal;
g) is identified by a pharmacy technician as someone who requires assistance or may face a risk
from the selection of use of a Schedule 3 drug or health care product, aid or device; or
b) any questions that require therapeutic knowledge, clinical analysis or assessment; and
c) anyone who indicates they are purchasing the Schedule 3 drug for an animal.
9.4 A pharmacy technician may enter into a dialogue with or provide information to a person who:
a) requests a health care product, aid or device;
b) requests assistance in making a choice about a health care product, aid or device;
c) appears to be having difficulty in making a choice about a health care product, aid or device; or
d) the pharmacy technician recognizes as someone who may face a risk from the selection or use
of a health care product, aid or device.
Application of Standard 10
10.1 The formula must include a calculation of the amount of each ingredient and a description of the process
of compounding that is specific enough to allow the process to be replicated in formulation and
production.
10.2 Whenever possible, a pharmacist or a pharmacy technician who compounds a drug or blood product
must do so according to a compounding formula from a reputable source such as a pharmacy text or
peer-reviewed published journal.
10.3 If no formula is available, a pharmacist must use the pharmacist’s pharmaceutical knowledge, including
but not limited to knowledge in pharmaceutics, pharmacology, medicinal chemistry and therapeutics to
create a formula and reduce it to writing.
10.4 Whenever possible, a pharmacist or a pharmacy technician who compounds a drug or blood product
must ensure that deviations from the written preparation process are avoided.
10.5 A pharmacy technician who determines that a deviation from the written formula, preparation process, or
expiry date may be required, must consult with and obtain the approval of the pharmacist before
preparing the compound.
10.6 If a deviation from the process is necessary, a pharmacist must use the pharmacist’s pharmaceutical
knowledge, including but not limited to knowledge in pharmaceutics, pharmacology, medicinal chemistry
and therapeutics to ensure the deviation is appropriate and will not negatively impact the stability or
therapeutic effectiveness of the preparation.
10.7 A pharmacist or a pharmacy technician who deviates from the written process while preparing a
compound must ensure that the deviation and the rationale for it are documented.
10.8 A pharmacist or a pharmacy technician who compounds a drug or blood product must ensure that all
ingredients used in compounding have an approved designation of standard of quality such as:
a) BP (British Pharmacopeia),
c) NF (National Formulary)
10.9 A pharmacist or a pharmacy technician who compounds a drug or blood product must ensure that a
beyond-use date based upon a reputable source of information such as a pharmacy text or a peer-
reviewed published journal is assigned to each compounded drug or blood product.
10.10 If no reputable source of information for a beyond-use is available, a pharmacist must use the
pharmacist’s pharmaceutical knowledge, including but not limited to knowledge in pharmaceutics,
pharmacology, medicinal chemistry and therapeutics to determine an appropriate beyond-use date.
10.11 In addition to the documentation requirements for dispensing a drug or blood product in Standards 18.1
and 18.2, a pharmacist or a pharmacy technician who compounds a drug or blood product must ensure
that a record is created that includes the:
a) name, lot number, expiry date and quantity of each ingredient used to prepare the compounded
drug or blood product;
d) a clear audit trail that identifies all individuals who were involved in the preparation and
verification of the compounded drug or blood product, and the role of each individual.
10.12 A pharmacist or a pharmacy technician who engages in sterile compounding of drugs or mixing other
products for parenteral or ophthalmic use, must do so in an environment and according to procedures
that meet the requirements of a reputable source such as the Canadian Society of Hospital Pharmacists
(CSHP), American Society of Health System Pharmacists, or the United States Pharmacopeia (USP).
10.13 Notwithstanding Standard 10.12, effective 180 days after Council approval of Guidelines for Preparing
Sterile Compounds, a pharmacist or a pharmacy technician who engages in sterile compounding of drugs
or mixing other products for parenteral or ophthalmic use, must do so in an environment and according to
procedures that meet the requirements of United States Pharmacopeia (USP) chapter 797 as outlined in
the Guidelines for Preparing Sterile Compounds.
10.14 A pharmacist or a pharmacy technician must perform a final check of all compounded drugs or blood
products to be satisfied that each step in the compounding process has been completed accurately by
verifying that:
a) the drug, strength, manufacturer and quantity compounded are correct;
b) the compound was correctly prepared according to the written formula and process;
e) the package and packaging material are appropriate to protect the compounded product from
light and moisture as necessary and to minimize the potential for interaction between a drug or
health care product and the container.
10.15 Whenever possible, a final check of a compounded product must be performed by a pharmacist or a
pharmacy technician who did not prepare the label, complete calculations, select the ingredients from
stock or prepare the compound.
10.16 Before compounding drugs for use for an animal, the pharmacist must determine:
a) whether an appropriate equivalent product, intended either for human or animal use, is
commercially available;
b) whether the formulation to be used is safe and appropriate for use in the animal species; and
Restriction on compounding for animals that may enter the food chain
b) any product that is an antimicrobial and is not a Health Canada approved product for use in
animals that may enter the food chain must not be used in compounding.
10.18 A pharmacist who compounds drugs for use in animals that may enter the food chain must ensure:
a) all ingredients in the compounds are safe for use in the animals and for subsequent human
consumption of the animals; and
b) an empirical drug withdrawal time is determined collaboratively with the prescribing veterinarian
if the compound contains an active pharmaceutical ingredient that leaves a drug residue.
Application of Standard 11
11.1 A pharmacist must understand the restrictions and requirements applicable to prescribing by
pharmacists set out in these standards and Section 16 of the Pharmacists and Pharmacy Technicians
Profession Regulation including:
a) adapting a prescription (s16(1)(e), (f), and 16(2));
11.2 A pharmacist who chooses to engage in prescribing must prescribe in accordance with these standards.
Adapting a prescription
11.3 In accordance with Standard 12, but subject to section 11.4, a pharmacist may prescribe a Schedule 1
drug by adapting a prescription from another prescriber by:
a) altering the dosage, formulation or regimen;
b) Schedule 2 drug, or
c) blood product
for an animal by adapting a prescription from another prescriber, except for the purposes of renewal for
continuity of care.
11.5 In addition to Standard 11.4, a pharmacist must not prescribe a drug that is a medically important
antimicrobial for an animal by adapting a prescription from another prescriber, for the purposes of
renewal for continuity of care.
Prescribing in an emergency
11.6 In accordance with Standard 13, a pharmacist may prescribe a Schedule 1 drug or blood product in an
emergency when:
a) there is an immediate need for drug therapy, and
b) it is not reasonably possible for the patient to see a prescriber to obtain a prescription.
11.7 Despite Standard 11.6, a pharmacist must not prescribe a Schedule 1 drug or blood product in an
emergency for an animal.
11.8 In accordance with Standard 14, a pharmacist who has received notification from the Registrar that the
pharmacist has been granted additional prescribing authorization may prescribe a Schedule 1 drug or
blood product at initial access or to manage ongoing therapy based on:
a) the pharmacist’s own assessment of the patient,
b) a recommendation from a prescriber that the patient receive a Schedule 1 drug or blood product,
or
11.9 Despite Standard 11.6 and notification from the Registrar, a pharmacist must not prescribe a Schedule 1
drug, Schedule 2 drug, or blood product at initial access or to manage ongoing therapy for an animal.
11.10 A pharmacist must not prescribe a drug or blood product unless the intended use:
a) is an indication approved by Health Canada,
11.11 A pharmacist must not prescribe any drugs listed in the schedules of the Controlled Drugs and Substances
Act including but not limited to drugs listed in the Narcotic Control Regulations and the Benzodiazepines
and Other Targeted Substances Regulations.
Fundamentals of prescribing
11.12 A pharmacist must only engage in prescribing a drug or blood product where the pharmacist:
a) has or develops a professional relationship with the patient,
b) has adequate knowledge and understanding of the condition being treated and the drug being
prescribed,
c) has adequate information about the patient’s health status and the disease or condition being
treated,
d) takes reasonable steps to be satisfied that the patient has enough information to participate in
the decision-making process and obtains the patient’s informed consent to prescribe,
e) is satisfied that the patient is not inappropriately seeking drug therapy from the pharmacist in
circumstances where that therapy has been refused by another prescriber, and
11.13 A pharmacist who prescribes a drug or blood product must communicate as soon as reasonably possible
to any regulated health professionals whose care of the patient may be affected by their prescribing
decision:
a) that they have prescribed for the patient,
11.14 A pharmacist who prescribes a drug or blood product must reduce the prescription to writing in a clear,
concise and easy-to- read format that includes all information required in a complete prescription as
outlined in Standard 6.7.
11.15 A pharmacist who prescribes a drug or blood product must document in the patient’s record:
a) the prescribing decision, the rationale for it and the information required in Standard 11.13;
Application of Standard 12
12.1 Notwithstanding Standard 12(a), a pharmacist who does not have an original prescription, but is satisfied
that:
a) the patient has presented evidence of current ongoing therapy based on a prescription (such as
an empty prescription vial),
i. for the patient to attend the pharmacy that dispensed the original prescription to obtain a
refill, or
ii. to have the prescription transferred from the pharmacy that dispensed the original
prescription,
b) only prescribe the minimum amount of the drug necessary to give the patient sufficient time to
attend the pharmacy that dispensed the original prescription or see the prescriber of the original
prescription.
12.3 In addition to the notification and documentation required in Standard 12.7, a pharmacist who renews a
prescription under Standard 12.1 must:
a) notify a pharmacist at the pharmacy that dispensed the original prescription, and
12.4 A pharmacist who receives the notification required in Standard 12.3(a) must document the information
on the patient’s record.
b) have sufficient knowledge about the patient’s health status and the disease or condition being
treated to make the decision to adapt the prescription,
e) be satisfied that the adaptation will maintain or enhance the effectiveness of the therapy,
f) be satisfied that the adaptation cannot reasonably be expected to cause a drug therapy problem,
g) be satisfied that the adaptation will not place the patient at increased risk,
h) be satisfied that the intended use of any drug or blood product prescribed in the process of the
adaptation is for an approved use as described in Standard 11.10, and
i. determine that the patient’s age, weight, or organ function necessitates a dosage
adjustment; or
12.7 In addition to the requirements for documentation outlined in Standards 11.13 to 11.15, a pharmacist who
adapts a prescription must:
a) provide a clear reference on the new prescription to the original prescription, and
b) retain both the new prescription and the original prescription where applicable.
Circumstancesthatdonotrequirenotificationtotheoriginalprescriber
12.8 Despite Standard 11.13, notification of the original prescriber and other health professionals is not
required:
a) for the substitution of a generic drug or blood product for a prescribed drug or blood product,
unless the prescriber has directed that there be no substitutions on the original prescription; or
b) for the substitution of one dosage form for another dosage form, unless the dosage form change
requires a change in regimen or dose.
Application of Standard 13
13.1 A pharmacist who has not been granted additional prescribing authorization who determines by gathering
sufficient information from a patient and from independent inquiries that:
a) there is an immediate need for drug therapy;
c) the patient is not inappropriately seeking drug therapy from the pharmacist in circumstances
where that therapy has been refused by another prescriber; and
13.2 In determining whether it is appropriate to prescribe for emergency purposes, a pharmacist must:
a) personally see and assess the patient,
b) explain the basis on which they intend to prescribe and obtain the patient’s informed consent,
c) obtain sufficient information about the patient’s health status and disease or condition to make
the decision to prescribe,
e) be satisfied that the prescription will not place the patient at increased risk,
f) be satisfied that the intended use of any drug or blood product prescribed is for an approved use
as described in Standard 11.10, and
13.3 To obtain adequate information for the purposes of Standard 11.12(c) a pharmacist who prescribes a
Schedule 1 drug or blood product in an emergency must conduct a patient assessment that includes
consideration of:
a) the information referred to in Standard 3;
b) physical qualities;
e) the date and extent of the last assessment of the condition by another regulated health
professional and the results of that assessment.
Restrictions on supply
13.4 In prescribing in an emergency, a pharmacist must only prescribe a limited and interim supply of a drug or
blood product for the patient so that the patient’s health or life is not at risk.
Obligationforfollow-upandnotification
b) refer the patient to another regulated health professional for additional care, or
13.6 A pharmacist who prescribes in an emergency must, as soon as reasonably possible, contact the patient’s
usual prescriber, where applicable, to communicate the information required in Standard 11.13.
Application of Standard 14
Conditionstobemetbeforeprescribingwithadditionalprescribingauthorizationoccurs
14.1 A pharmacist must not prescribe at initial access or to manage ongoing therapy unless:
a) the prescribing decision is in the best interests of the patient, and
b) the pharmacist has taken the appropriate steps to maintain patient safety.
14.2 A pharmacist who prescribes a Schedule 1 drug or blood product for a patient at initial access or to
manage ongoing therapy must:
a) see the patient personally at the time of prescribing,
b) have seen the patient personally in the past and have developed a professional relationship over a
period of time, or
c) have a strong collaborative relationship with a regulated health professional acting within the
scope of their profession who regularly sees the patient in person.
Requirement of an assessment
14.3 To obtain adequate information for the purposes of Standard 11.12(c), a pharmacist who prescribes a
Schedule 1 drug or blood product at initial access or to manage ongoing therapy must conduct a patient
assessment that includes consideration of:
a) the information referred to in Standard 3,
b) physical qualities,
e) the date and extent of the last assessment of the condition by another regulated health
professional and the results of that assessment.
14.4 A pharmacist who prescribes at initial access or to manage ongoing therapy must take reasonable steps
to:
a) determine which other regulated health professionals the patient is consulting, and
b) communicate as soon as reasonably possible to any regulated health professionals whose care
of the patient may be affected by their prescribing decision the information required in Standard
11.
AdditionalrequirementsapplicabletoprescribingunderSection14(a)
14.5 In addition to meeting the requirements under Standards 14.1 to 14.4 inclusive, a pharmacist who
prescribes at initial access based on the pharmacist’s own assessment of the patient must:
a) in the case of a previously diagnosed condition, endeavor to develop a collaborative relationship
with other regulated health professionals identified under Standard 14.4; and
b) in the case of a condition that was not previously diagnosed, refer the patient to another
regulated health professional if diagnosis or further treatment by another regulated health
professional is necessary.
AdditionalrequirementsapplicabletoprescribingunderSection14(b)
14.6 In addition to meeting the requirements under Standards 14.1 to 14.4 inclusive, a pharmacist who
prescribes based on the recommendation of another authorized prescriber must:
a) receive a written recommendation from the prescriber or reduce a verbal recommendation to
writing,
c) develop a collaborative relationship with the prescriber to obtain diagnostic and other relevant
health information and to determine mutual goals for therapy.
AdditionalrequirementsapplicabletoprescribingunderSection14(c)
14.7 In addition to meeting the requirements under Standards 14.1 to 14.4 inclusive, a pharmacist who
prescribes based on collaboration with another regulated health professional must:
a) confirm that the health professional is a regulated member of a college with whom the Alberta
College of Pharmacy has a memorandum of understanding in relation to collaborative
prescribing, and
b) develop a collaborative relationship with that other regulated health professional to obtain
diagnostic and other relevant health information and to determine mutual goals of therapy.
Obligationforfollow-upandnotification
14.8 When a pharmacist prescribes at initial access or to manage ongoing therapy, the pharmacist must:
a) develop a follow-up plan with the patient including parameters that will be monitored, expected
outcomes and time frames; and
b) be satisfied that there is ongoing monitoring by a regulated health professional acting within the
scope of their profession.
14.11 A pharmacist must not prescribe a Schedule 1 or Schedule 2 drug at initial access or to manage ongoing
therapy for a patient that is an animal.
Application of Standard 15
15.1 A pharmacist who dispenses a drug that the pharmacist prescribed at initial access based on the
pharmacist’s own assessment of the patient must:
a) have advised the patient that the patient may choose to have the prescription dispensed by
another pharmacist,
b) take reasonable steps to be satisfied the patient has enough information to participate in the
decision-making process,
d) document compliance with each step of the dispensing process required under Standard 7.
Application of Standard 16
16.1 A pharmacist who administers a drug, blood product or vaccine must have in place and be prepared to
implement current policies and procedures for handling emergencies.
16.2 A pharmacist who administers a drug, blood product or vaccine must, at a minimum, review the policies
and procedures required under Standard 16.1 annually.
16.3 A pharmacist who administers a drug, blood product or vaccine must ensure that the environment within
which the drug, blood product or vaccine will be administered is clean, safe, appropriately private and
comfortable for the patient.
Application of Standard 17
Steps required for the safe administration of a drug, blood product or vaccine
17.1 A pharmacist who administers a drug, blood product or vaccine to a patient must:
a) obtain informed consent from the patient;
b) be satisfied that there has been compliance with Standard 6 in relation to the appropriateness of
the drug, blood product or vaccine that will be administered;
c) take appropriate steps to ensure the patient is given the right drug, blood product or vaccine, for
the right reason, in the right dose, at the right time, using the right route.
17.2 In addition to the requirements in Standard 17.1, a pharmacist who is authorized to administer drugs by
injection who administers an injection to a patient must:
a) ensure that:
i. there is ready access to drugs and health care products, aids and devices used to treat
reactions to injectable drugs, blood products and vaccines; and
ii. the pharmacist is trained to administer the drugs and use the health care products, aids
and devices used to treat reactions to injectable drugs, blood products and vaccines, and
to manage reactions to injectable drugs, blood products, and vaccines;
iii. has been stored and labeled appropriately prior to and following reconstitution or mixing,
Routineprecautionsforinfectioncontroldefined
17.3 For the purpose of Standard 17(2)(c), routine precautions for infection control include precautions to help
prevent the spread of infection, including but not limited to:
a) handling all body fluids and tissues as if they were infectious, regardless of the patient’s
diagnosis;
b) washing hands before and after caring for the patient, and after removing gloves; and
c) wearing gloves when required to prevent contact with body fluids, excretions or contaminated
surfaces or objects.
17.4 Following the administration of a drug, blood product or vaccine, a pharmacist must:
a) ensure the patient is appropriately monitored;
c) ensure devices, equipment and any remaining drug, blood product or vaccine is disposed of
safely and appropriately;
d) document the administration in the patient record as required in Standard 18 and Appendix A; and
e) provide relevant information to other regulated health professionals and provincial health
agencies as appropriate.
Noinjectionforachildyoungerthanfiveyears
17.5 A pharmacist authorized to administer drugs by injection must not administer an injection to a child
younger than five years old.
17.6 A pharmacist authorized to administer drugs by injection must not administer a drug, blood product or
vaccine to a patient that is an animal.
Application of Standard 18
Transaction record
18.1 Each time a pharmacist or a pharmacy technician dispenses a Schedule 1 drug or blood product, the
pharmacist or the pharmacy technician must ensure that a written transaction record is created that
includes:
a) the name of the patient for whom the drug was dispensed, or in the case of a herd of animals, a
unique identifier or the location of the herd;
a pharmacist who:
i. drug therapy problems identified and/or interventions, monitoring plans or actions related
to drug therapy problems;
18.4 In addition to the requirements set out in this standard, a patient record must meet the requirements of
Appendix A.
18.5 When a record of patient care is amended after the fact to correct an error the following must be
identifiable:
a) the original entry,
b) the identity of the pharmacist or the pharmacy technician who made the alteration, and
18.6 A pharmacist or a pharmacy technician must keep the patient record accurate and current with regard to
the pharmacist’s or the pharmacy technician’s activities.
b) in a manner that facilitates sharing, ease of use and retrieval of patient information by authorized
individuals.
18.8 A pharmacist or a pharmacy technician who provides professional services in an institution pharmacy, as
defined in the Pharmacy and Drug Act, or in an environment with other regulated health professionals who
have a shared medical or patient record may:
a) document the pharmacist’s or pharmacy technician’s activities in the institution’s medical record
or the shared medical or patient record for the patient; and
b) rely upon documentation within the drug distribution system and the institution’s medical record
or the shared medical or patient record if the pharmacist or pharmacy technician is satisfied that
the information required in Standards 18.1, 18.3, and 18.4 is available to the pharmacist or the
pharmacy technician.
18.9 A pharmacist or a pharmacy technician who provides professional services in an environment with other
regulated health professionals who share a medical or patient record must:
a) determine ownership of the patient record, and
b) collaborate with other regulated health professionals to ensure the creation and maintenance of
patient records meet the requirements outlined in these standards.
b) ensure the records are created, stored and maintained in a manner that meets or exceeds the
requirements outlined for record keeping in the Standards for the Operation of Licensed
Pharmacies;
ii. two years past the age of majority of the patient whichever is greater;
d) retain the record for a period of not less than 10 years after the last pharmacy service if the
patient is an animal; and
e) create a plan for transfer of the records when they cease the practice.
i. The plan must include provision of notice to the college of the location of the patient
records and how they may be accessed when the transfer occurs.
Application of Standard 19
19.1 After a drug, health care product, aid or device has been dispensed or sold, neither a pharmacist nor a
pharmacy technician may:
a) accept that drug or health care product for reuse, or
19.2 Despite Standard 19.1, a pharmacist or a pharmacy technician may repackage a drug, health care product,
aid or device for reuse if:
a) the drug, health care product, aid or device will be reused only for the patient for whom it was
originally dispensed; or
b) the drug or health care product, aid or device is in a tamper-resistant package and was provided
to a health care facility and maintained under the control of a regulated health professional at all
times while in that facility; and
c) the pharmacist or pharmacy technician is confident that the drug or health care product:
ii. has been stored in a manner that would not adversely affect its stability.
19.3 Standard 19.1 does not apply to a drug that was dispensed for a patient by an institution pharmacy, as
defined in the Pharmacy and Drug Act, if the pharmacist or pharmacy technician is satisfied that the drug
distribution system is adequate to ensure the integrity of the drug and the safety of any patient who may
receive the drug.
Application of Standard 20
Providing direction
b) be authorized to perform the restricted activities that the pharmacy technician will provide under
the pharmacist’s direction;
c) ensure the pharmacy technician’s involvement in restricted activities is limited to those activities
authorized by regulation;
d) ensure there is a system in place in the pharmacy that complies with these Standards and the
Standards for the Operation of Licensed Pharmacies including:
B. assesses each patient, the patient’s health history, and medication record and
determine that the drug therapy provided is appropriate for the patient;
C. counsels the patient and monitors the patient’s drug therapy; and
E. requires that the pharmacy technician being provided direction reports to them;
and
ii. ensuring that the involvement of the pharmacy technician in the restricted activities
authorized by regulation can be monitored and assessed; and
e) in the case of a courtesy pharmacist, not provide direction to a pharmacy technician unless the
courtesy pharmacist has been authorized in writing by the Registrar to do so and the
authorization has been indicated in the courtesy pharmacist register.
20.3 A student pharmacist or a provisional pharmacist is authorized to perform, within the practice of
pharmacists and in accordance with these Standards, the restricted activities authorized by regulation
under the supervision of a clinical pharmacist or courtesy pharmacist.
20.4 A clinical pharmacist or a courtesy pharmacist who supervises a pharmacy student or a provisional
pharmacist must ensure:
a) the pharmacist is registered on the student register or the provisional register,
b) the duties being supervised and the method of supervision, either direct or indirect, are in
accordance with this Standard and the rules of the Structured Practical Training Program
established under Section 10 of the Pharmacists and Pharmacy Technicians Profession
Regulation, and
20.5 A courtesy pharmacist is authorized to perform, within the practice of pharmacists and in accordance
with these Standards, the restricted activities referred to in the Regulation without supervision if the
restricted activity is directly related to the purpose for which the courtesy pharmacist is registered on the
courtesy pharmacist register.
20.6 A student who is enrolled in a pharmacy technician program approved by Council or a provisional
pharmacy technician is authorized to perform, within the practice of pharmacy technicians and in
accordance with these Standards, the restricted activities authorized by regulation under the supervision
of a clinical pharmacist, courtesy pharmacist or pharmacy technician.
20.7 A clinical pharmacist, a courtesy pharmacist, or a pharmacy technician who supervises a provisional
pharmacy technician must ensure:
a) the technician is registered on the provisional technician register, and
b) the duties being supervised and the method of supervision, either direct or indirect, are in
accordance with this Standard and the rules of the Structured Practical Training Program
established under Section 10.1 of the Pharmacists and Pharmacy Technicians Profession
Regulation.
20.8 A clinical pharmacist, a courtesy pharmacist, or a pharmacy technician who supervises a student
pharmacy technician must ensure:
a) the student pharmacy technician is registered in a training program approved by the Council, and
b) that direct supervision is provided in accordance with this Standard and the rules of the
Structured Practical Training Program established under Section 10.1 of the Pharmacists and
Pharmacy Technicians Profession Regulation.
20.9 A courtesy pharmacy technician is authorized to perform, within the practice of pharmacy technicians
and in accordance with the Standards of Practice, the restricted activities authorized by regulation under
the direction of a pharmacist but only if the restricted activity that is being performed is directly related to
the purpose for which the regulated member is registered on the courtesy pharmacy technician register.
20.10 A clinical pharmacist or a courtesy pharmacist who supervises an employee must ensure that if the
employee engages in compounding a drug, providing a drug for sale, or selling a drug under the
pharmacist’s supervision the employee does not engage in any component of the activity which requires
the training and skills of a pharmacist or a pharmacy technician.
20.11 Despite Standard 20.10, an individual employed in a pharmacy is also permitted to perform the restricted
activities described in Standard 20.10 with the consent of and under the direct supervision of a pharmacy
technician if
a) a clinical pharmacist or courtesy pharmacist consents to the activity being performed by the
individual under the direct supervision of a pharmacy technician, and
20.12 An employee engaged in selling a drug or providing a drug for sale must do so under the direct
supervision of a clinical pharmacist, a courtesy pharmacist or a pharmacy technician and must not
engage in any component of those restricted activities other than assisting the pharmacist or the
pharmacy technician by:
a) placing a drug into stock,
b) entering information into the information management system about the sale of a drug,
20.13 An employee engaged in compounding a drug or blood product must do so under the direct supervision
of a clinical pharmacist, a courtesy pharmacist or a pharmacy technician and must not engage in any
component of those restricted activities other than by assisting the pharmacist or the pharmacy
technician by:
a) selecting a drug from stock,
d) entering information into the information management system about the act of compounding.
Supervision rules
20.14 A regulated member who consents to provide direct supervision under this Standard must
a) be authorized to perform the restricted activity being supervised,
d) ensure that the individual who is supervised complies with the Standards of Practice,
f) be able to observe and promptly intervene and stop or change the actions of the individual who is
under supervision.
20.15 In addition to 20.14(a) to (d), a regulated member who consents to provide indirect supervision under this
Standard must
a) have procedures in place
i. that comply with the Standards of Practice and the Standards for the Operation of
Licensed Pharmacies, and
ii. that ensure the safety and integrity of the dispensing or compounding of drugs by the
individual who is under supervision,
b) ensure that the procedures described in Standard 20.15(a) are complied with by the individual
who is being indirectly supervised, and
c) be readily available for consultation by the individual who is under supervision and, if advisable,
for providing hands-on assistance to the individual.
20.17 Pharmacy technicians who assist a pharmacist in the transfer of a prescription to another pharmacist
must:
a) only transfer prescriptions when directed to do so by the pharmacist that they are assisting;
i. a copy of the prescription as written by the prescriber or as reduced to writing in the case
of verbal prescriptions;
iv. the name and address of the pharmacist that is transferring the prescription; and
v. any other information that the transferring pharmacist deemed necessary under Standard
2.9(b); and
d) render the prescription inactive to ensure that no further sales are made under the prescription
and the prescription is not transferred to another pharmacist;
e) document that the prescription has been transferred in the patient record including:
i. the name and location of the pharmacist to whom the prescription was transferred;
iii. the name of the pharmacy technician assisting the pharmacist with the transfer.
Application of Standard 21
21.1 A pharmacist or a pharmacy technician who repackages a drug or blood product must ensure that in
respect of that drug or blood product there is sufficient documentation to provide a clear audit trail of the
repackaging process.
21.2 The documentation required under Standard 21.1 must identify:
a) drug information from the original container including:
b) all individuals involved in the repackaging and verification process and the role of each individual.
21.3 A pharmacist or a pharmacy technician who dispenses or sells a repackaged drug or blood product must
ensure that each repackaged drug or blood product has a label affixed to the package that meets the
requirements of a prescription label required under Standard 7 or that explicitly identifies the following:
a) a description of the drug, in English, by:
i. generic name, strength and the identity of the manufacturer for a single-entity drug or
blood product; or
ii. generic name, strength and the identity of the manufacturer for a combination drug or
blood product, where possible, or the brand name and strength;
c) a lot number that links to the audit trail described in Standard 21.1; and
21.4 A pharmacist or a pharmacy technician who engages in repackaging drugs or blood products for sale to
patients must ensure that the label includes a direction statement which has on it the words:
“Take or use [insert the manufacturer’s suggested doses or use] or as directed by the prescriber.”
21.5 A pharmacist or a pharmacy technician must perform a final check of all repackaged drugs, blood
products or health care products to be satisfied that each step in the repackaging process has been
completed accurately by verifying that:
a) the drug or health care product, dosage form, strength, manufacturer and quantity packaged is
correct;
b) the information on the label is accurate according to the original container, including the drug,
dosage form, strength and manufacturer;
d) the package and packaging material are appropriate to protect the drug or health care product
from light and moisture as necessary and to minimize the potential for interaction between a drug
or health care product and the container.
21.6 Whenever possible, a final check of repackaged products must be performed by a pharmacist or
pharmacy technician who did not create the label or select the drug from stock.
21.7 A pharmacist or a pharmacy technician must ensure that, when dispensed to a patient, individually
packaged medications which include a drug (such as a lollipop) are:
a) individually labeled with the name of the drug or compound, lot number and expiry date; and
Application of Standard 22
22.1 A pharmacist who inserts or removes instruments, devices or fingers beyond the anal verge or beyond the
labia majora to administer a drug or medication under this standard must
a) have the informed consent of the patient;
b) document the consent and describe the steps taken in sufficient detail to allow transfer of care to
a physician or nurse practitioner; and
22.2 A pharmacist must not insert or remove instruments, devices or fingers beyond the anal verge or beyond
the labia majora under any circumstances for a patient that is an animal.
Application of Standard 23
23.1 A pharmacist or pharmacy technician who has reasonable grounds to believe the conduct of another
regulated member or another regulated health professional includes the procurement or performance of
female genital mutilation has a duty to report such conduct to the complaints director of the College or
the college applicable to the other regulated health professional.
7 Female genital mutilation is defined in the Health Professions (Protecting Women and Girls) Amendment Act.